Latest Axitinib Stories
NEW YORK, Nov. 19, 2010 /PRNewswire-FirstCall/ -- Pfizer Inc.
BURLINGTON, Mass., Nov.
WALTHAM, Mass., June 29 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, through 2019, robust 4.1 percent annual growth in the renal cell carcinoma drug market will be driven primarily by the uptake of GlaxoSmithKline's Votrient/Patorma, the launches of premium-priced emerging therapies and an increase in diagnosed incidence and treatment rates.
CALGARY, May 26 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY) announced today that the Cancer Therapy & Research Center at the University of Texas Health Science Center in San Antonio (CTRC) has started patient enrolment in a U.S.
NEW YORK, May 20 /PRNewswire-FirstCall/ -- Pfizer Oncology (NYSE: PFE) will present new data highlighting the company's focused approach to cancer drug development through the identification and validation of molecular targets.
BOULDER, Colo., April 22 /PRNewswire/ -- Clovis Oncology, Inc. and Ventana Medical Systems, Inc.
WALTHAM, Mass., Feb.
WALTHAM, Mass., Sept.14 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues finds that, following its launch and uptake, GlaxoSmithKline's angiogenesis inhibitor Votrient (formerly Armala) will garner sales of $640 million by 2018 and will take significant market share away from Pfizer's Sutent.
CALGARY, March 25 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY) today announced the completion of patient enrolment in its U.K.
Pfizer Inc today provided the latest update to its development pipeline, showing significant progress in achieving the company's growth, productivity and performance goals. The pipeline now includes 114 programs, from Phase 1 through Registration.
- Monstrous in size or character; huge; prodigious; monstrously perverse, savage, cruel, etc.